(21767351), A. M. A., (10696501), D. A., (832403), D. A., (9545771), A. H., (15468195), A. A., & (14777224), M. A. Y. (2024). Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: Model focused on reducing pain episode costs from Qatar’s healthcare perspective.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)(21767351), Ahmad M Adel, Dina Abushanab (10696501), Daoud Al-Badriyeh (832403), Anas Hamad (9545771), Awni Alshurafa (15468195), و Mohamed A Yassin (14777224). Cost-effectiveness of L-glutamine Versus Crizanlizumab for Adults with Sickle Cell Disease: Model Focused on Reducing Pain Episode Costs from Qatar’s Healthcare Perspective. 2024.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)(21767351), Ahmad M Adel, et al. Cost-effectiveness of L-glutamine Versus Crizanlizumab for Adults with Sickle Cell Disease: Model Focused on Reducing Pain Episode Costs from Qatar’s Healthcare Perspective. 2024.